KDR and liver cancer: 90% of the BRAF mutations comprise of the specific BRAFV600E point mutation, which is a contributor to uncontrolled proliferation and angiogenesis.102 Sorafenib (51), a protein kinase inhibitor with activity against VEGFR, PDGFR and RAF kinases and approved for the treatment of kidney and liver cancers, was initially developed for inhibition of RAF.